CFTR and cystic fibrosis: In this frame, we tested two CFTR correctors, VX661 (Tezacaftor) and VX809 (Lumacaftor) presently on the market in formulation with the potentiator VX770 (Ivacaftor) for CF patients bearing the ΔF508 mutation of CFTR [28,48].